Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ac-225-PSMA-62 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on Ac-225-PSMA-62, a putative radioligand therapy targeting PSMA (Jun 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ac-225-PSMA-62 | Ac225-PSMA-62|225Ac-PSMA-62 | Limited information is currently available on Ac-225-PSMA-62, a putative radioligand therapy targeting PSMA (Jun 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06229366 | Phase I | Ac-225-PSMA-62 | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL) | Recruiting | CAN | 0 |